Showing 611-620 of 839 results for "".
- Myze Launches 'The Daily Lid Wipe' for Eyelid Hygienehttps://modernod.com/news/myze-launches-the-daily-lid-wipe-to-elevate-daily-eye-care-partnering-with-leading-eye-health-experts/2482543/In a move to prioritize eyelid hygiene and make it a core component of everyday self-care routine, myze has unveiled its first branded product, The Daily Lid Wipe. The Daily Lid Wipe, formulated with input from dry eye experts Laura M. Periman, MD, and Cecelia Koett
- Oklahoma Neonatologist-Researcher Earns NIH Grant to Advance Retinopathy of Prematurityhttps://modernod.com/news/oklahoma-neonatologist-researcher-earns-nih-grant-to-advance-retinopathy-of-prematurity/2482537/Faizah Bhatti, MD, was the first to discover the presence of surfactant protein A in the eye–a key protein related to blood vessel growth and previously believed to only exist in the lung. Now, the University of Oklahoma neonatologist and researcher has earned a 5-year, $2.3 million grant f
- Epion Presents Survey on Keratoconus Highlighting Need for Accessible Treatmentshttps://modernod.com/news/epion-presents-survey-on-keratoconus-highlighting-urgent-need-for-accessible-treatments/2482518/Jonathan H. Talamo, MD, Chair of the Board at Epion Therapeutics, presented findings at the Eyecelerator@AAO 2024 conference on the current state of keratoconus (KC) management in the United States, highlighting a critical gap in treatment for the progressive eye disease. Results f
- Oculis to Provide Update on DIAMOND Phase 3 Program for OCS-01 Eye Drops at Innovate Retina and Eyecelerator 2024https://modernod.com/news/oculis-to-provide-update-on-diamond-phase-3-program-for-ocs-01-eye-drops-at-innovate-retina-and-eyecelerator-2024/2482488/Oculis announced an update on its DIAMOND phase 3 program for OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology for the treatment for diabetic macular edema (DME). David Eichenbaum, MD, an expert in retina diseases, will present new insig
- 4DMT Announces Phase 2 PRISM Interim Results for Intravitreal 4D-150 in Wet AMDhttps://modernod.com/news/4dmt-announces-phase-2-prism-interim-results-for-intravitreal-4d-150-in-wet-amd/2482364/4D Molecular Therapeutics announced initial interim 24-week landmark data from the population extension cohort of the PRISM phase 2 clinical trial, which evaluated intravitreal 4D-150 in a broad wet AMD patient population. The data were presented by Raj K. Maturi, MD, at the A
- Opthea Welcomes International Retina Thought Leaders to Its Medical Advisory Boardhttps://modernod.com/news/opthea-welcomes-international-retina-thought-leaders-to-its-medical-advisory-board/2482361/Opthea announced the formation of its Medical Advisory Board, which will comprise of 10 retina thought leaders from countries around the world, including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medica
- Regeneron Backs $500 Million Venture Capital Fund for Biotechnology Innovationhttps://modernod.com/news/regeneron-backs-500-million-venture-capital-fund-for-biotechnology-innovation/2482234/Regeneron Ventures announces its formation as a venture capital fund focused on promising biopharmaceutical, health care and health technology companies. The fund’s general partner will be independently managed by former Regeneron executives Jay S. Markowitz, MD, and Michael Aberman, M
- Robotic Cataract Surgery Using ForSight Robotics’ Oryom Platform Presented for the First Time at ASCRShttps://modernod.com/news/robotic-cataract-surgery-using-forsight-robotics-oryom-platform-presented-for-the-first-time-at-the-ascrs-annual-meeting/2482229/Robotic cataract surgery using ForSight Robotics’ Oryom platform on a porcine eye was presented at the 2024 ASCRS annual meeting by David F. Chang, MD, marking the debut of this technology at a professional conference. During
- Oculis Announces Positive Results from Phase 3 Trial of Once Daily Treatment for Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-positive-results-from-phase-3-trial-of-once-daily-ocs-01-for-treatment-of-inflammation-and-pain-following-cataract-surgery/2482221/Oculis announced positive results from the phase 3 OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 ASCRS annual meeting in Boston. Eric Donnenfeld, MD, presented the “Once Daily OCS-01, an OPTIREACH F
- Adverum Announces Positive Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-positive-preliminary-efficacy-and-safety-data-from-luna-phase-2-trial-of-ixo-vec-in-patients-with-wet-amd/2482107/Adverum Biotechnologies announced preliminary safety and efficacy data from the ongoing LUNA phase 2 trial in patients with wet age-related macular degeneration (AMD). These data are being presented by Arshad Khanani, MD, today at the 47th Annual Meeting of the Macula Society. The presentation, t